All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia

Seminars in Hematology

Volumn 38, Issue 1, 2001, Pages 13-25

  Fenaux, Pierre ^a   Chomienne, Christine ^a,b   Degos, Lament ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DEXAMETHASONE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; DOSE RESPONSE; ERYTHEMA NODOSUM; FEVER; HUMAN; HYPOTENSION; KIDNEY FAILURE; LEG EDEMA; LEUKEMIA CELL; LEUKOCYTE; MYOSITIS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RISK FACTOR; THROMBOCYTOSIS; TREATMENT PLANNING; WEIGHT GAIN;

EID: 0035145435     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90002-2     Document Type: Article

References (78)

1. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule
2. Hypercalcaemia due to all-trans retinoic acid
3. Acute promyelocytic leukemia relapse in the central nervous system during hematologic and molecular remission
4. Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia
5. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
6. Proposals for the classification of the acute leukemias
7. A variant form of hypergranular promyelocytic leukemia (M3)
8. Molecular monitoring of the myl/retinoic acid receptor alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction
9. Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia
10. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
11. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;7) translocations using real-time RT-PCR
12. A PML/RARa fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia
13. All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias. I. Clinical results
14. 2) in acute promyelocytic leukemia
15. 3) exerts dose-dependent dual effects on APL cells
16. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients
17. All trans retinoic acid in promyelocytic leukemias. II. In vitro studies structure function relationship
18. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia
19. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients
20. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital
21. Incidence, clinical features, and outcome of all-trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia
22. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid
23. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
24. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
25. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMENA-AIEOP multicenter "AIDA" trial. GIMENA-AIEOP multicenter "AIDA" trial
26. Modulation of IL-6 and IL-1b and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia
27. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia
28. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed promyelocytic leukemia
29. Proof of differentiating mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis
30. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
31. Extramedullary disease in acute promyelocytic leukemia
32. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases
33. A randomized comparison of all-trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
34. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia
35. Long term follow up confirms the benefit of all trans-retinoic acid in acute promyelocytic leukemia
36. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
37. Treatment of acute promyelocytic leukemia: A report on 70 cases
38. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia
39. Prolonged follow up confirms that all transretinoic acid (ATRA) followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia (APL)
40. Multiple thrombosis in acute promyelocytic leukaemia after tretinoin
41. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study
42. The "retinoic acid syndrome" in acute promyelocytic leukemia
43. Association of PML-RARalpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study
44. Erythema nodosum associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia
45. Aggressive daunomycin (DNR) therapy improves survival in acute promyelocytic leukemia (APL), a Southwest Oncology Group (SWOG) trial
46. Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia
47. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
48. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
49. Role of maintenance chemotherapy in acute promyelocytic leukemia
50. All-trans retinoic acid induced thrombocytosis in a patient with acute promyelocytic leukaemia
51. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia - The occurrence of retinoic acid syndrome is a risk factor
52. In vivo treatment of human acute promyelocytic leukemia with a histone deacetylase inhibitor, FR9011228
53. Combined retinoic acid and arsenic therapy sharply enhances survival in a mouse apl model
54. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2
55. Effect of high dose AraCX in APL
56. Fournier's gangrene during induction treatment of acute promyelocytic leukemia, a case report
57. Extramedullary involvement in patients with acute promyelocytic leukemia: A report of seven cases
58. Therapy of molecular relapse in acute promyelocytic leukemia
59. Tretinoin toxicity in children with acute promyelocytic leukaemia
60. Molecular remission in PML/RARalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
61. Leucémie aiguë promyélocytaire: Étude rétrospective de 119 malades traités par daunorubicine
62. Myositis with tretinoin
63. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia
64. CD 56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
65. The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study
66. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia
67. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: Results from intergroup protocol 0129
68. Clinical study of 9-cis retinoic acid (LGD 1057) in acute promyelocytic leukemia
69. Acute promyelocytic leukemia
70. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: Clinical experience with a new synthetic retinoid, AM-80
71. All trans-retinoic acid in acute promyelocytic leukemia
72. The thrombophilic state in acute promyelocytic leukemia
73. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
74. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation
75. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid
76. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid)
77. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
78. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience